Please login to the form below

Not currently logged in
Email:
Password:

Afferent Pharma

This page shows the latest Afferent Pharma news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’ s chronic cough drug clears mid-stage trial. MK-7264 reduces coughs per hour by 37%. ... Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating now the drug

Latest news

  • Merck buys cough drug developer Afferent for $1.25bn Merck buys cough drug developer Afferent for $1.25bn

    Merck buys cough drug developer Afferent for $1.25bn. Gains access to pipeline with potential for development in ‘ neurogenic’ indications. ... Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics